Telix Pharmaceuticals (TLX) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.
The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.
Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.
Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。